That above anti viral is BCRX. I have done considerable work and find almost all Vaccines that I can tell target the Spike Protein. Here are 2 bios of interest trying something different-)
Several companies, including the
California-based Gritstone Bio, have decided to take a more targeted tack, selecting a subset of coronavirus traits to package into some of their repertoire of inoculations. One of Gritstone’s vaccines, which is currently in human trials, contains not only spike but also chunks of
two proteins that the coronavirus keeps in its interior: one called nucleocapsid, which helps the pathogen package its genetic material, and another called ORF3a, which helps newly formed coronavirus particles mosey out of cells.
T cells are already an essential part of the immune response our bodies mount to our current vaccines, because they react very strongly to spike. But Andrew Allen, Gritstone’s CEO, told me that the T cells in our bodies could be doing
more,if given the chance. T cells in people who have been infected by the coronavirus can home in on
many parts of the virust hat aren’t packaged into most vaccines. Some of these immune targets, encouragingly, have mutated more slowly than spike, raising hopes of protection that’s both potent and long-lived. Early studies suggest that new coronavirus variants that bamboozle certain antibodies are still
nowhere near stumping the body’s diverse cavalry of T cells.
A) Gritstone bio, Inc. (GRTS)
NasdaqGS - Nasdaq
11.12+0.28 (+2.58%)
At close: November 26 1:00PM EST
11.30+0.18 (+1.62%)
After hours:Nov 26, 04:55PM EST
Another company, California-based
Immunity Bio, plans to push the pro-T-cell paradigm even further. It has several versions of a
spike-nucleocapsid combo vaccine in clinical trials, some of which are being delivered as drops into the mouth, and will soon be testing out an intranasal spray. Patrick Soon-Shiong, the company’s CEO, told me that this route of administration is a much better pantomime of how the coronavirus actually enters the human body—through the airway, where it will encourage the production of unique populations of antibodies and T cells tailor-made to guard these tissues. Many of those T cells will even
hunker down in and around the lungs, where they can head off the virus immediately, something that
doesn’t happen as efficiently when we inject vaccines into our deltoids. “I think local immunity is going to be what we need, if we’re thinking ahead,” Donna Farber, an immunologist at Columbia University, told me. Some next-generation vaccines could operate as solo acts for the un-immunized; others could be boosters for people whose defenses against the coronavirus are no longer up to snuff.
B) ImmunityBio, Inc. (IBRX)
NasdaqGS - Nasdaq
W
6.50+0.15 (+2.36%)
At close: November 26 1:00PM EST
6.55+0.05 (+0.77%)
After hours:Nov 26, 04:56PM EST
Amyris takes bite out of sharks with Covid vaccine joint venture-
Nov 8, 2021, 5:14pm EST
The East Bay company's synthetic biology work, coupled with RNA technology it has licensed, could help Patrick Soon-Shiong's
ImmunityBio produce a Covid vaccine.
